Skip to content

Prospective, randomized, controlled, double-blind clinical study of traditional Chinese medicine combined with glucocorticoid in the treatment of generalized myasthenia gravis

Prospective, randomized, controlled, double-blind clinical study of traditional Chinese medicine combined with glucocorticoid in the treatment of generalized myasthenia gravis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048709
Enrollment
Unknown
Registered
2021-07-13
Start date
2021-07-31
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Interventions

Sponsors

Zhejiang Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The first onset meets the diagnostic criteria for generalized myasthenia gravis; 2. Complete admission data, detailed condition description, complete disease course record and no obvious missing items; 3. Application of glucocorticoid therapy; 4. Aged over 18 years old; 5. The diagnosis of GMG was re-verified by at least two attending physicians or higher-level physicians based on typical clinical phenotypes and laboratory test results.

Exclusion criteria

Exclusion criteria: 1. Patients with other neuromuscular diseases or peripheral neuropathy; 2. Combined with serious cardiovascular and cerebrovascular, liver, kidney and hematopoietic system diseases, chronic severe infection, mental illness; 3. Pregnant or lactating women; 4. Those who use other immunosuppressants; 5. The application of traditional Chinese medicine including traditional Chinese medicine or acupuncture has been started before enrollment; 6. Those who have been enrolled in other clinical intervention studies and have conflicts with the observation of this topic; 7. Those who meet any of the above items will be excluded.

Design outcomes

Primary

MeasureTime frame
the relapse rate after hormone reduction,The incidence rate of hormone complications,and conversion rate of Myasthenia gravis crisis;Myasthenia gravis quantitative score (qMGS),;myasthenia gravis complex scale (MGC);myasthenia gravis muscle scale (MMS);myasthenia gravis absolute and relative score (ARS-MG);

Secondary

MeasureTime frame
MG daily life scale (MG-ADL);

Countries

China

Contacts

Public ContactHou Qun

Zhejiang Provincial Hospital of Traditional Chinese Medicine

houqun168@163.com+86 13588887283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026